Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 19 of 19 matching drugs for TLR9 — including drugs targeting any of its 12 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging TLR9 Direct 2
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) TLR9 Direct 1
binimetinib, hydroxychloroquine TLR9 Direct 1
chloroquine TLR9 Direct 1
chloroquine, radiotherapy, temozolomide TLR9 Direct 1
cobimetinib, hydroxychloroquine, atezolizumab TLR9 Direct 1
gemcitabine, abraxane, hydroxychloroquine TLR9 Direct 1
gemcitabine, hydroxychloroquine, nab-paclitaxel, paricalcitol TLR9 Direct 1
hydroxychloroquine, gemcitabine TLR9 Direct 1
hydroxychloroquine, radiotherapy TLR9 Direct 1
hydroxychloroquine, temozolomide, pharmacological study, radiation TLR9 Direct 1
paclitaxel protein bound, gemcitabine, cisplatin, hydroxychloroquine TLR9 Direct 1
paricalcitol, hydroxychloroquine, losartan, neoadjuvant therapy and surgery only (control) TLR9 Direct 1
hydroxychloroquine TLR9 Direct yes 0
hydroxychloroquine sulfate TLR9 Direct yes 0
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.